EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and biotech venture capital firm Claris Ventures (“Claris”) today announced an acceleration framework to streamline programmes from Claris’s portfolio companies into the clinic through Evotec’s fully integrated platform.
- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and biotech venture capital firm Claris Ventures (“Claris”) today announced an acceleration framework to streamline programmes from Claris’s portfolio companies into the clinic through Evotec’s fully integrated platform.
- Claris’s portfolio is focused on biotech companies with programmes approaching clinical trials and currently consists of nine biotech companies across Italy, Switzerland, and the UK.
- Evotec is already supporting Claris’s portfolio company IAMA Therapeutics (“IAMA”), a Genoese Biotech company focused on innovative medicines for brain disorders.
- Building on this success, the acceleration framework agreement now provides Claris’s other portfolio companies with easy access to Evotec’s full range of integrated services.